The Economist
According to Bain & Company's Jason McLinn, the Bayer-Johnson case could hand big chemicals companies an advantage. The increased cost of testing in the development process will likely force out smaller players in the space over time.
The Economist
According to Bain & Company's Jason McLinn, the Bayer-Johnson case could hand big chemicals companies an advantage. The increased cost of testing in the development process will likely force out smaller players in the space over time.